Description of China Biologic Products Holdings Inc's Business Segments
China Biologic Products Holdings Inc. is a premier player in the biopharmaceutical sector in China, primarily centered on the research, development, manufacturing, and marketing of an extensive array of plasma-derived biopharmaceutical products. The companys offerings are organized into distinct segments, covering a comprehensive suite of products and services that underline its commitment to addressing critical healthcare needs.
Segments
1. Human Plasma-based Products This segment is the cornerstone of China Biologic’s portfolio, encompassing a wide variety of products derived from human plasma. The primary offerings include:
- Human Albumin: Essential for maintaining oncotic pressure in the blood, human albumin therapy is vital for patients suffering from burns, trauma, liver cirrhosis, and other conditions that lead to fluid loss.
- Immunoglobulin Products: These are critical for patients with immune deficiencies or those undergoing treatments that suppress immune function. The varieties offered include: - Intravenous Immunoglobulin (IVIG): Used to treat a range of autoimmune and immunodeficiency disorders. - Subcutaneous Immunoglobulin (SCIG): An alternative to IVIG for patients who benefit from a self-administered therapy. - Hepatitis B Immunoglobulin: Utilized in post-exposure prophylaxis for hepatitis B virus.
- Coagulation Factors: Indispensable for managing blood disorders, especially hemophilia. Key products include: - Fibrinogen Concentrate: Important in managing bleeding in patients with fibrinogen deficiency. - Prothrombin Complex Concentrate: Used to treat bleeding episodes in patients receiving anticoagulation therapy. - Factor VIII: A crucial factor for hemophilia A patients.
Other Plasma-based Products This segment expands the companys reach to include various other plasma-derived products that cater to both medical and non-medical needs. Noteworthy products include:
- Human Rabies Immunoglobulin: Essential for post-exposure treatment in rabies cases. - Tetanus Immunoglobulin: Used for the prevention of tetanus in at-risk populations. - Varicella-Zoster Immunoglobulin: Important for protecting immunocompromised patients from chickenpox complications.
Regenerative Medicine This emerging segment highlights the companys commitment to innovative therapeutic avenues. The products under this category are derived from stem cell research and have potential applications in treating various conditions, including:
- Neurological Diseases: Such as spinal cord injuries and neurodegenerative disorders. - Orthopedic Conditions: Tissue regeneration in injuries and degenerative bone diseases. - Cardiovascular Diseases: With the aim of repairing damage to heart tissue following heart attacks.
Products
- Human Albumin: The companys product line includes both human serum albumin and advanced human recombinant albumin variants tailored for clinical use.
- Immunoglobulin: A robust selection of immunoglobulin therapies designed to respond effectively to a multitude of clinical scenarios, enhancing patient immunity.
- Coagulation Factors: A comprehensive suite designed to ensure effective treatment options for individuals with bleeding disorders.
- Other Plasma-based Products: These specialized products provide essential therapeutic support across a range of infectious diseases.
- Stem Cell Products: These biologics, including stromal vascular fraction (SVF) and placental mesenchymal stem cells (PMSCs), are promising tools in regenerative therapies.
Services
1. Plasma Collection Services China Biologic currently maintains over 40 plasma collection centers across the nation. These centers are critical for sourcing high-quality plasma from voluntary donors, ensuring a steady supply for their product lines.
Contract Manufacturing Services The company offers its expertise through contract manufacturing services tailored for other biopharmaceutical firms. These services encompass a broad range of capabilities, including:
- Processing Services: Utilizing advanced technologies in the production of plasma-derived products. - Testing and Quality Assurance: Employing rigorous testing protocols to guarantee product safety and efficacy. - Analytical Services: Providing in-depth analytical support to ensure compliance with regulatory standards.
Conclusion In summary, China Biologic Products Holdings Inc. is a formidable entity in the biopharmaceutical landscape, excelling in the manufacture and supply of plasma-based products. With a diverse portfolio ranging from human albumin and immunoglobulins to coagulation factors and regenerative medicine solutions, the company is well-positioned to meet the evolving needs of global healthcare. Its ancillary services, including plasma collection and contract manufacturing, further enhance its operational capabilities, solidifying its role as a key contributor to the health and well-being of patients both in China and beyond.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
